Egle Therapeutics is a spin-out of Institut Curie in France, developing immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
Approach: Treg immune modulation.
Indications: Oncology and autoimmune diseases.
The company has already announced a corporate strategic research alliance with Takeda with the goal of validating novel tumor-infiltrating regulatory Treg targets against which Takeda will develop potential therapies.
Egle’s flagship program focuses on the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
Established in 2020, the start-up results from Eliane Piaggio’s research work, as Inserm Research Director & Head of the Translational Immunotherapy Team at Institut Curie, and Luc Boblet, a serial biotech entrepreneur.
Subscribe for alerts on new companies featured on Startups.Bio
- Archon BiosciencesArchon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to… Read more: Archon Biosciences
- Cytospire TherapeuticsFounded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune… Read more: Cytospire Therapeutics
- This Week in Biotech Venture CapitalThe biotech sector continues to see a strong flow of new venture… Read more: This Week in Biotech Venture Capital
- THRONCATTHRONCAT is a new startup that aims to transform the field of… Read more: THRONCAT